KalVista Pharmaceuticals Inc’s recent filing unveils that its 10% Owner Venrock Healthcare Capital Par acquired Company’s shares for reported $0.24 million on Apr 09 ’25. In the deal valued at $9.42 per share,25,000 shares were bought. As a result of this transaction, Venrock Healthcare Capital Par now holds 5,303,985 shares worth roughly $66.25 million.
Then, Palleiko Benjamin L sold 6,669 shares, generating $79,828 in total proceeds. Upon selling the shares at $11.97, the CHIEF EXECUTIVE OFFICER now owns 287,811 shares.
Before that, Audhya Paul K. sold 2,394 shares. KalVista Pharmaceuticals Inc shares valued at $23,988 were divested by the CHIEF MEDICAL OFFICER at a price of $10.02 per share. As a result of the transaction, Audhya Paul K. now holds 102,940 shares, worth roughly $1.29 million.
JMP Securities initiated its KalVista Pharmaceuticals Inc [KALV] rating to a Mkt outperform in a research note published on January 31, 2025; the price target was $19. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. BofA Securities began covering KALV with “Buy” recommendation on December 18, 2024. H.C. Wainwright started covering the stock on June 15, 2020. It rated KALV as “a Buy”.
Price Performance Review of KALV
On Tuesday, KalVista Pharmaceuticals Inc [NASDAQ:KALV] saw its stock fall -4.66% to $12.49. Over the last five days, the stock has lost -4.51%. KalVista Pharmaceuticals Inc shares have risen nearly 47.46% since the year began. Nevertheless, the stocks have risen 2.63% over the past one year. While a 52-week high of $15.50 was reached on 04/30/25, a 52-week low of $7.30 was recorded on 01/13/25. SMA at 50 days reached $11.97, while 200 days put it at $11.07.
Levels Of Support And Resistance For KALV Stock
The 24-hour chart illustrates a support level at 12.21, which if violated will result in even more drops to 11.92. On the upside, there is a resistance level at 12.91. A further resistance level may holdings at 13.32. The Relative Strength Index (RSI) on the 14-day chart is 51.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.26, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 58.53%. Stochastics %K at 63.05% indicates the stock is a holding.
The most recent change occurred on July 29, 2019 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
